EHVA fosters a multidisciplinary approach to the challenge of developing broadly effective HIV vaccines.
EHVA’s programme primary goals are to:
- To develop a Multidisciplinary Vaccine Platform (MVP) for prophylactic and therapeutic HIV vaccines
- To move at least two novel prophylactic vaccine candidates to clinical development
- To identify immune correlates associated with control of HIV replication following immunological intervention
- To establish astrong scientific basis for further development of EHVA vaccine candidates in larger clinical trials